Introduction and hypothesis Vitamin D is an important micronutrient in muscle function. We hypothesize that vitamin D deficiency may contribute to fecal incontinence (FI) symptoms by affecting the anal continence mechanism. Our goal was to characterize the association of vitamin D deficiency as a variable affecting FI symptoms and its impact on health-related quality of life (HR-QoL 
Introduction
Fecal incontinence is the involuntary leakage of solid or liquid stool and is the second most common pelvic floor disorder, with an estimated prevalence of 9 % in US women aged 20-59 years, increasing to 14.4 % in women between 60 and 79 years [1, 2] . The etiology of fecal incontinence (FI) is multifactorial; however, dysfunction of the anal continence mechanism is a likely contributor. The anal continence mechanism primarily involves proper function of the anal sphincter complex, which is composed of the internal anal sphincter (IAS), the external anal sphincter (EAS), and the puborectalis muscles [3] .
Vitamin D is a fat-soluble micronutrient that plays a vital role in calcium homeostasis in smooth and skeletal muscle. In vitro studies suggest that serum vitamin D may impact skeletal muscle functional efficiency by regulating calcium homeostasis to affect muscle contractility and by protecting the muscle cellular environment against insulin resistance and inflammation. This relationship has been translated clinically as skeletal muscle efficiency, and its function improves with vitamin D supplementation in community dwelling women with insufficient serum vitamin D [4, 5] .
The Institute of Medicine concluded that a serum vitamin D level of ≥ 20 ng/ml was adequate for bone health. A normal serum vitamin D level is ≥30 ng/ml, whereas levels ≤ 29 ng/ml defines an insufficient vitamin D status [6] . Vitamin D insufficiency has become an epidemic in the United States, affecting 78 % of geriatric adults and up to 80 % of reproductiveage women [7, 8] . Vitamin D deficiency (serum vitamin D level ≤ 20 ng/ml) is a more severe form of vitamin D insufficiency and is also a major public health issue, with prevalence rates up to 39 % in US adults aged 18-50 years [9] .
Vitamin D insufficiency/deficiency has received increased attention for its association with various extraskeletal medical conditions, with the most notable impact being on musculoskeletal health [10] [11] [12] [13] [14] . Vitamin D receptors are found in skeletal and smooth muscle, such as the puborectalis and anal sphincter muscles, which are essential in anal continence [15] . Human in vitro studies consistently demonstrate that vitamin D regulates calcium homeostasis, suggesting that serum vitamin D levels may have a role in smooth and striated muscle contraction, differentiation, and growth [4, 10, 16] . Level I-II clinical studies also support the important role of vitamin D in the efficiency of muscle function [4, [17] [18] [19] . Together, these data support the biologic plausibility behind recent hypotheses that vitamin D has a role in optimal muscle health.
Insufficient/deficient vitamin D levels have been associated with increased colorectal and anal symptom distress in women with pelvic floor disorder symptoms, including FI [8, 20] . Further investigations exploring the relationship between FI and deficient vitamin D levels are important. Our objectives were to evaluate the impact of vitamin D status on FI symptoms in women and characterize the relationship of deficient vitamin D status with FI severity and anal sphincter function among women with FI.
Materials and methods

Study population
Participants in this study were women seen in the Urogynecology Care Clinic at the University of Alabama at Birmingham between 2007 and 2011. All participants were identified by Current Procedural Terminology (CPT) codes to have had a total serum vitamin D level reported within 1 year of their evaluation in our clinic. Serum vitamin D panels were performed as a part of primary care screening independent of our practice. This study was approved by the Institutional Review Board. All serum vitamin D panels were processed in the same outpatient laboratory using liquid chromatography [7, 9] . The 25(OH)D panel included total 25(OH)D (primary outcome measure) as well as 25(OH)D 2 and D 3 fractions [10, 16, 21] . The same assay was used throughout the entire study period. Investigators performed a retrospective electronic medical record (EMR) review of women with vitamin D levels for inclusion and exclusion criteria. All participants were women with at least one visit who were >19 years and had a serum vitamin D level reported within 1 year of their visit. The Urogynecology Care Clinic saw women for general gynecology care (controls) in addition to caring for women with pelvic floor conditions (cases). In order to specifically investigate women with FI symptoms, women were excluded if they had pelvic floor symptoms without FI symptoms or were missing clinical data. To increase the external validity and generalizability of our data, women were excluded if they had any medical conditions known to impair vitamin D absorption or metabolism or to be a major cause of FI, including: stage ≥ 3 chronic kidney disease (CKD), chronic liver disease, gastric bypass, colovaginal fistula, and pelvic irradiation.
Variable definitions
For this case-control study, groups were composed based on the presence or absence of FI symptoms. Fecal incontinence was defined as the complaint of involuntary loss of solid or liquid stool according to the International Urogynecological Association and the International Continence Society definitions [2] . Cases were defined as women with FI symptoms evaluated in our Genitorectal Disorders Clinic, a specialty clinic within the Urogynecology Care Clinic. All women seen at this clinic are referred by providers for evaluation and characterization of FI. This evaluation includes completion of standardized questionnaires, anorectal manometry, and endoanal ultrasound, as indicated. Controls were women without FI or any other pelvic floor symptoms and who were seen for general gynecologic care.
The main area of interest, vitamin D deficiency, was defined as a total serum vitamin D level ≤ 20 ng/ml [22] . Women with total serum vitamin D levels ≥ 30 ng/ml were classified as being vitamin D sufficient; women with serum levels between 21 and 29 ng/ml were grouped as vitamin D insufficient. Total serum vitamin D level needed for general muscle health is yet to be defined, thus these definitions were extrapolated from bone-health data.
Using a standard data form, the EMR was abstracted to obtain demographic, medical, and laboratory data. Demographic (i.e., age, height, weight, parity, and ethnicity) and medical characteristics were obtained from the initial history and physical examination documentation. Ethnicity was categorized as non-Hispanic white or African American. Body mass index (BMI) was calculated and reported as kilograms/square meter. Medical characteristics abstracted for cases were: (1) number of major medical conditions (obtained from past medical history), and (2) number of prescription/over-the-counter medications to include calcium and/or vitamin D supplementation taken regularly (obtained from the medication reconciliation documentation). In addition to the serum vitamin D level, laboratory data included a single value for glomerular filtration rate (GFR) reported as milliliters/minute/1.73 2 . If more than one GFR was present, we used the reported value closest to the date of the vitamin D level report.
Women in the case group completed the Modified Manchester Health Questionnaire (MMHQ), and results were abstracted from the EMR to characterize FI, its severity, and impact on quality of life (QoL). The MMHQ is a validated measure that includes the Fecal Incontinence Severity Index (FISI) [23] and measures health-related QoL (HR-QoL) for FI, with eight subscales: overall impact, role, physical, social, relationships, emotion, sleep/energy, and severity/adaptation. Total and subscale scores are scaled from 0 to 100, with higher scores representing greater impact on HR-QoL. The FISI component measured the severity of liquid, solid, mucus, or gas incontinence, with severity scale varying from two or more times per day, once per day, two or more times per week, once a week, to one to three times per month. Patientweighted scores were used to determine symptom severity, with scores ranging from 0 to 61, where higher scores indicate worse FI severity. A FISI score of 0 indicates continence [23] . Anal manometry assessed anal sphincter function and anal sensation and was performed by a physician using a waterperfused disposable catheter system (Medtronic, Inc, Minneapolis, MD, USA). Pressures were recorded 2 cm from the anal verge during resting, squeezing, and pushing. Rectal capacity was measured in milliliters using an air-filled balloon. To evaluate for disruption of IAS and EAS, endoanal ultrasonography (EAUS) was performed using a 10-MHz, 360°window, endoanal probe at 5-mm intervals (B&K Medical Systems, Inc, Wilmington, MA, USA).
Statistical analysis
Student's t test and Fisher's exact chi-square test were used for continuous and categorical variables, respectively, to compare demographic and medical condition characteristics between cases and controls. Unconditional logistic regression was used to calculate odds ratios (OR) and 95 % confidence intervals (CIs) for the association between vitamin D deficiency and FI in primary analyses. Two logistic models were created: One model used dichotomous vitamin D deficiency as the dependent variable, and women with insufficient serum vitamin D (levels between 21 and 29 ng/ml) status were excluded in order to elicit the most significant clinical effect of vitamin D deficiency on FI symptoms. The second model used continuous serum vitamin D levels as the dependent variable. In a secondary analysis among cases, anorectal manometry pressures and MMHQ data were compared between cases that were and were not vitamin D deficient (level ≤ 20 ng/ml) using the Wilcoxon rank-sum test. Analyses were performed using SAS v9.3 (Cary, NC, USA).
Results
Six hundred and fifteen women were identified as patients evaluated in the Urogynecology Care Clinic who had a serum vitamin D level drawn within 1 year of their visit, and 374 were eligible for inclusion (Fig. 1 ). Of these 374 eligible women, 44 met the case definition of having FI, and 103 met the control definition of not having any pelvic floor disorder symptoms. After excluding women with insufficient but not deficient vitamin D levels, 31 in the case group and 81 in the control group were included in the primary analysis. There were no demographic or medical differences between these groups. Mean [± standard deviation (SD)] age and BMI of the group combined was 60.3±1. Our primary analysis aimed to identify whether vitamin D deficiency was a variable associated with FI symptoms. Case serum vitamin D levels were significantly lower than in the control group [ (Fig. 2) .
To investigate symptom impact of vitamin D deficiency on QoL of women with FI symptoms (cases), we compared validated questionnaire data of women with sufficient and deficient vitamin D levels. MMHQ data ( Table 2) showed higher total and subscale-specific scores in women with vitamin D deficiency. Women with vitamin D deficiency also sustained a greater negative impact from FI symptoms, greater social limitations, and greater effect of FI on sleep and energy compared with women with sufficient vitamin D levels. FISI scores were also higher in women with deficient vitamin D Fig. 1 Study population. Bold data indicate the study groups i.e. the deficient and sufficient groups were used, not the insufficient groups for primary outcome analyses To explore a possible mechanism of how vitamin D deficiency may affect FI symptoms in women, we compared diagnostic characteristics measured by anal manometry of women with FI and vitamin D deficiency (n=11) to those with sufficient serum vitamin D levels (n=20). We found that the mean resting pressure at 2 cm was 33.7±19.3 mmHg in vitamin -deficient-women and 33.6±13.7 mmHg in vitamin-D-sufficient women with FI (p=0.99). Mean squeeze pressures at 2 cm were lower in the former (60.7±32.3 mmHg) compared with the latter (73.9±23.2 mmHg), group but this difference did not achieve statistical significance (p=0.21). Vitamin-D-deficient women with FI also had a lower mean change between resting and squeeze pressures at 2 cm (27.0 ± 22.1 mmHg) compared with vitamin-Dsufficient women with FI (40.3±21.2 mmHg), p=0.12. [24] . Studies of the impact of vitamin D deficiency on FI symptoms are lacking. We previously reported findings of a separate retrospective cohort study in which we found that colorectal symptoms, including FI symptoms, were significantly more severe in women with vitamin D insufficiency than vitamin-D-sufficient women (p=0.03) [20] . Our prior data also align with our findings of higher total MMHQ and FISI scores in vitamin-D-deficient women with FI.
Vitamin D increases skeletal muscle cell proliferation and muscle fiber size in vitro [15, 25] . It is therefore biologically plausible for vitamin D serum levels to affect muscle efficiency by binding to the vitamin D receptor, resulting in muscle growth [15, 25] . This hypothesis may explain a potential contribution to the mechanism behind our observation of increased odds of vitamin D deficiency in women with FI symptoms compared with in controls. Women with vitamin D deficiency may have less efficient use of the anal sphincter muscle complex, thus potentially increasing the frequency and severity of FI symptoms. The trends observed in the exploratory analysis of anal manometry squeeze pressures between vitamin-D-deficient and -sufficient women with FI are important hypothesis-generating findings that may support this theory. In addition to lower squeeze pressures among women with FI and deficient vitamin D levels, we observed a nonsignificant but smaller mean change in anal sphincter pressure from rest to squeeze in comparison with women with sufficient vitamin levels. The clinical implications of this data are limited because the differences observed did not reach statistical significance, which is likely due to our small sample. Thus, this data should be used as the basis of future research.
In light of these results, this study should be viewed with certain strengths and limitations: It is strengthened by the use of a control group to investigate the relationship between vitamin D nutritional status and FI, which extends the literature on this topic beyond case reports and cross-sectional studies. Our control group was of similar ethnic diversity, geographic origin, age, BMI, and number of medical comorbidities as our case population, which strengthens comparison between groups. It is further strengthened by the robust data collected on the case group to include validated measures of FI symptom severity and impact on HR-QoL; anal manometry, which provides data regarding anal sphincter function; and EAUS to evaluate for anal sphincter injury; EAS injury was present in very few women with FI.
It is estimated that only 30 % of women with symptomatic FI seek care [26] . As a consequence, this study is limited by the small sample size of the case group; however, our sample size did allow for a one-case to two-controls comparison. It is plausible that some women with FI may have been included in the control group. However, because board-certified urogynecologists were providing primary gynecologic care for women included in that group, it is likely that screening questions were included in the history and physical examination and, if present, FI would have been identified and investigated. Generalized screening for vitamin D insufficiency or deficiency is not currently supported by evidence; therefore, screening standards are variable among primary care providers, which further limited our sample size. The potential of selection bias is inherent in the study design, as women who present for evaluation may have more severe symptoms than those who do not present for care. This may potentially result in an overestimation or underestimation of the effect observed. The case-control design is also limited by the lack of definitive causality. Finally, there was a lack of obstetric data for the control group (such data was reliably reported in the EMR), and stool consistency as a contributor to FI was not accounted for.
Conclusion
This hypothesis-generating case-control study demonstrated that vitamin D deficiency was present in a significant proportion of women seeking treatment for FI symptoms and had a negative impact on their QoL. Prospective studies are warranted to further explore this relationship between vitamin D deficiency and more severe FI symptoms. Specifically, further studies of anal physiology are needed to increase our understanding of the impact of vitamin D on anal sphincter function. With further study, vitamin D supplementation may prove to be an important adjunctive therapy to pelvic floor exercises, biofeedback, anal sphincteroplasty, sacral neuromodulation, and pharmacologic therapy for treating FI.
